Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. Mai 2020 07:30 ET | Quelle: Biogen Inc.

New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS

Patients treated with VUMERITY® (diroximel fumarate) and TECFIDERA® (dimethyl fumarate) showed a significant reduction of gadolinium-enhancing lesions compared to baselineAdditional data show improved...
18. Mai 2020 07:30 ET | Quelle: Biogen Inc.

New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients

Treatment with SPINRAZA improved or stabilized motor function across patient populations, including young adultsThe longer-term safety profile of SPINRAZA was consistent among a broad spectrum of ages...
27. April 2020 16:06 ET | Quelle: Biogen Inc.

Biogen Prices $3.0 Billion of Senior Unsecured Notes

CAMBRIDGE, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the pricing of two series of senior unsecured notes for an aggregate principal amount of $3.0 billion....
20. April 2020 17:45 ET | Quelle: Biogen Inc.

Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics

Continued to improve absolute environmental performance across energy, water and waste metrics while growing the business in 2019; has remained carbon neutral for six years in a rowAdvanced health...
16. April 2020 07:30 ET | Quelle: Biogen Inc.

Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank

Biogen employees, family members, and other close contacts can contribute blood samples and medical data to aid efforts to rapidly understand and overcome COVID-19 Biobank to provide scientists with...
02. April 2020 07:30 ET | Quelle: Biogen Inc.

Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study

DEVOTE will evaluate the safety and potential for even greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy (SMA)Well-established safety profile and proven...
16. März 2020 16:08 ET | Quelle: Biogen Inc.

Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World

Most of the funds will be directed to support the global response and the immediate needs of communities hardest hit by COVID-19 CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Biogen Inc....
27. Februar 2020 16:06 ET | Quelle: Biogen Inc.; Sangamo Therapeutics, Inc.

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including...
13. Januar 2020 07:30 ET | Quelle: Biogen Inc.

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.

PF-05251749 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms across various psychiatric and neurological diseases Biogen to pay Pfizer...
13. Dezember 2019 07:30 ET | Quelle: Biogen Inc.

Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy

CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 2 PASSPORT study of gosuranemab (BIIB092) for progressive supranuclear...

Vorherige Seite